500
Participants
Start Date
July 16, 2021
Primary Completion Date
October 19, 2024
Study Completion Date
February 3, 2025
Riociguat (Adempas, BAY63-2521)
Follow clinical practice.
Mount Sinai, New York
NYU Langone, New York
Columbia, New York
Northwell Health, New Hyde Park
Winthrop, Mineola
University of Rochester, Rochester
Allegheny General Hospital, Pittsburgh
Temple University, Philadelphia
Richmond Pulmonary Associates, Richmond
VCU/MCV, Richmond
AnMed Health Medical Center, Anderson
University of Missouri, Columbia
St Francis Medical Ctr, Columbus
Advent Health, Orlando
CCF (Cleveland Clinic Florida), Weston
Tampa General Hospital USF, Tampa
Norton Pulmonary Specialists, Louisville
University of Cincinnati, Cincinnati
Beaumont Hospital, Troy
Advocate Aurora, Milwaukee
Froedtert/Medical College of Wisconsin, Milwaukee
Loyola, Maywood
Advocate Christ, Oak Lawn
Northwestern, Chicago
St. Louis University, St Louis
Barnes / Wash U, St Louis
KUMC, Kansas City
UNMC, Omaha
Integris, Oklahoma City
Premier Pulmonary, Denison
Baylor Scott and White, Plano
UT Southwestern, Dallas
Houston Methodist, Houston
Seton Heart, Austin
Banner University Medical Center- Phoenix, Phoenix
Honor Health, Phoenix
Univ of Arizona College of Medicine, Tucson, Tucson
UNMH, Albuquerque
Cedar Sinai, Los Angeles
USC, Los Angeles
UCSD, San Diego
UC Irvine, Irvine
Santa Barbara Cottage Hospital, Santa Barbara
UCSF, Fresno
UC Davis, Sacramento
Legacy Health, Portland
Providence, Spokane
Mass General, Boston
Boston University, Boston
Alliance Pulmonary, Guaynabo
Lead Sponsor
Xcenda, LLC
UNKNOWN
Bayer
INDUSTRY